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Nitric oxide (NO), a small molecule being generated ubiquitously, targets a plethora of 
tissues to regulate both physiological and pathophysiological functions. NO 
overproduction, stimulated by microenvironmental conditions, is the main component 
that dysregulates the tight balance between its beneficial and damaging role in ocular 
homeostasis. Considering the protective functions of NO against glaucoma, its 
endogenous release facilitates aqueous humor drainage and regulates ocular blood flow 
maintaining a normal intraocular pressure. NO overproduction generates free radicals, 
such as peroxynitrite, that induce a vicious circle of vascular disharmony and 
dysregulation, transient ischemia, nitrosative stress, neuronal degeneration and 
permanent glaucomatic injury.  Helicobacter pylori (Hp) is considered a burdening 
factor of glaucoma.  NO overproduction and systematic possible dispersion in Hp 
infection (Hp-I) could suggest a potential pathophysiological bridge between these 
conditions. In this review, the authors aim to decode the role of NO in glaucoma in 
respect to the Hp-I, with the perspective to countenance and stimulate further studies. 
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INTRODUCTION 
Nitric oxide (NO), a small (30 Da) anion radical, is expressed ubiquitously. It is 
involved in many physiological and pathophysiological pathways. As a 
gasotransmitter, it is a principal modulatory molecule s involved in mammalian 
biology, especially in the nervous, cardiovascular, and immune systems1–6. NO plays a 
physiological role in neuronal cell signaling. However, its overproduction induces 
neuronal energy compromise resulting in diverse neurodegenerative pathologies. NO is 
critical in the various functioning of the central nervous system (CNS). Toxic beyond 
certain levels, it contributes to pathophysiology in the context of inflammatory 
disorders. It also affects aging and neurodegeneration in the CNS7–9. 
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NO-synthase (NOS), an intracellular cytochrome P450 enzyme, mediates NO 
production by catalyzing L-arginine to L-hydroxyarginine and further to NO and 
citrulline transformation10. NOS is divided into three NOS archetypal isoforms: (1) 
neuronal NOS (nNOS or NOS-1); (2) inducible NOS (iNOS or NOS-2); and (3) 
endothelial NOS (eNOS or NOS-3). Each isoform is associated with a set of 
characteristics and expression patterns11,12.  nNOS and eNOS, are constitutively 
expressed; the third is induced by specific stimulants. nNOS, as the etymology reveals, 
is primarily found in the nervous system. It is essential for neuronal signaling by 
involvement in neurotransmission in astrocytes and neurons. The endothelial 
localization of eNOS is important for vasodilation and blood pressure control. The 
release of NO from eNOS under basal conditions  regulates: organ blood flow 
distribution in the cardiovascular and renal system; inhibition of platelet aggregation, 
platelet and leukocyte adhesion and smooth muscle cell proliferation at the vascular 
level; and induction of natriuresis and diuresis in the kidneys12,13. Intracellularly, eNOS 
is detected in the Golgi complex, plasma membrane. It is attached to the mitochondrial 
membrane in various concentrations6,14.  
In contrast, iNOS is not constantly present in cells. It is only (over-) expressed when 
the cell is induced or stimulated, characteristically, by proinflammatory cytokines 
and/or bacterial lipopolysaccharide (LPS)15,16. In addition, it is overexpressed in 
response to different inflammatory stimuli. Nanomolar amounts of NO are generated 
by nNOS and eNOS for short periods of time (seconds to minutes) in a 
calcium/calmodulin (CaM)-dependent manner3,16. In contrast, upon triggered, iNOS 
induces substantial and delayed amounts of NO (micromolar range) up to several hours  
until the enzyme’s degradation17. The produced amount of NO enhances the defense 
against invading pathogens. Therefore, it is critical for the inflammatory response and 
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the innate immune system. An inappropriately excessive NO concentration or 
dysregulation of iNOS can lead to toxic effects and is linked with a variety of diseases15. 
The dual activity of iNOS-related NO (beneficial vs. detrimental) is highly 
concentration-dependent. Therefore, regulation of its production is important for both 
maintaining its proper physiological functions and controlling its deleterious effects. 
NO’s neutral chemical affinity, stability and size allows its unimpeded diffusion 
through and beside cells using heme scavenging proteins like hemoglobin as buffers6,18. 
The initial, non-selective effect of NO-induced biochemical cascade on target cells is 
the activation of soluble guanyl cyclase to produce cyclic guanosine monophosphate 
(cGMP)19. More specifically, NO orchestrates a plethora of biological operations in 
main cellular compartments (i.e. nucleus, cytoplasm, mitochondria and cellular 
membrane)  with an impact on overall cellular function, such as the inhibition of the 
mentioned platelet and neutrophil aggregation, relaxation of smooth muscles and 
regulation of the endothelial permeability6,20,21. In neural tissue it serves as a protective 
Janus molecule against degeneration and cellular death. In high concentration it induces 
reactive oxygen species (ROS) production and cytotoxicity4,22,23. NO becomes toxic 
after undergoing oxidation-reduction reactions with ROS to create noxious molecules 
recognized as reactive nitrogen species (RNS). The term  “nitrosative stress” has been 
introduced to describe the cellular damage/toxicity owing to NO and RNS overload24,25. 
Excess of NO and/or the creation of RNS (e.g., peroxynitrite [ONOO-], damages 
mitochondrial functioning. This, in combination with nuclear events, contributes to the 
neuronal cell metabolism disturbance and survival, promoting the pathogenesis of 
many neurodegenerative diseases14. ONOO- mediates most of the toxic actions of NO.  
It is the microenvironment and its alterations that affect NO’s formation, concentration, 
half-life and final action, whether subsidiary or harmful26,27. Normally, low 
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concentrations and a transient generation of NO regulate its actions to target cells. In 
contrast, inflammatory condition includes massive and perpetual NO secretion in high 
concentrations and nitrosative stress27. Although cGMP cascade remains the primary 
pathway of NO’s cellular activity, secondary pathways have also been described; S-
nitrosylation of proteins controls apoptosis, vascular resistance, and inflammation28,29. 
Specifically, NO’s predominant function is mediated via activation of the mentioned 
cyclic guanyl cyclase. This signals a pathway and S-nitrosylation of various proteins 
being implicated in cellular homeostasis and in mitochondrial biology. Examples of 
NO-related mediators triggering neuronal cellular death involved in several 
neurodegenerative diseases include11,14:  
• Increased mitochondrial fragmentation and autophagy via S-nitrosylation 
of important proteins like dynamin-related protein 1 and Parkin/PINK1 
(protein phosphatase and tensin homolog-induced kinase 1) complex 
• Formation of ONOO- involved in mitochondrial permeability transition and 
induction of nuclear toxicity with consequent release of apoptosis-inducing 
factor from mitochondria  
• Activation of parthanatos 
• Negative consequences on electron transport chain 
• Glutamate neurotoxicity 
• Changes in the mitochondrial metabolic pathways such as Krebs and urea 
cycles.  
Glaucoma, a neurodegenerative disease, is characterized by progressive retinal 
ganglion cell (RGC) apoptotic death. This results in a cupping of the optic disk and 
blindness30,31. Ocular physiology sustains a perpetual and indestructible circle of 
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aqueous humor (AH) production by the ciliary body -the anterior portion of the uveal 
tract located between the iris and the choroid- passage from posterior chamber to the 
anterior chamber through the pupil. Drainage occurs at the anterior chamber angle 
through the human trabecular meshwork (H-TM) and Schlemm´s canal (SC), 
intrascleral channels, and episcleral and conjunctival veins30,32. Although complex 
pathophysiological aspects have not been completely illuminated, the dysregulation of 
the normal AH flow and intraocular pressure (IOP) is considered the main axis of 
glaucomatic disease30. AH outflow disruption, due to increased H-TM resistance or 
drainage pathway obstruction, conveys mechanical tension to the posterior ocular 
structures especially to the lamina cribrosa. This suppresses the axonal supply of 
neurotrophic factors within the RG cell axons. It is followed by a perpetual biochemical, 
inflammatory, and apoptotic degeneration of the RG cells30. The mechanical theory 
stresses the importance of direct IOP-related increased compression of the axonal fibers 
and support structures of the anterior optic nerve, with distortion of the lamina cribrosa 
plates and interruption of axoplasmic flow. This leads to RGC death33. Although this 
simplified cascade seems conceivable, it is only the tip of the iceberg. Molecular aspects 
and provocative events have not been clarified. Microcirculation disorders, altered 
immunity, excitotoxicity, and oxidative stress are considered to be involved30. 
Focus on NO-related glaucoma pathophysiology, a potential physiologic target of NO, 
as vasodilator, is the H-TM being strictly controlled by the balance between vascular 
dilators and constrictors(the endothelin [ET])34. NO is a cotransmitter of smooth muscle 
relaxation in the chamber angle. It may be implicated in the regulation of AH  
dynamics35. Both NO and ET appear to be regulators of ocular blood flow. Under 
normal settings, the vasodilating effect of NO is counterbalanced by the 
vasoconstricting effect of ET36. On the other hand, in the occurrence of free radicals, 
 8 
NO creates toxic agents which provoke the TM metabolic states and modify its motility 
and function36,37. 
Proposed mechanisms of NO induced ocular homeostasis, after activation of cGMP 
cascade, include potassium kinetics’ control, osmotic changes and the H-TM 
relaxation. These facilitate aqueous drainage and reduce IOP by regulating TM cells 
contractility and volume38–40. These physiological principles have raised the hypothesis 
that NO signaling malfunction could result in H-TM rigidity and increased IOP, which 
predisposes glaucoma. In this regard, permanent ocular injury could be a result of the 
vascular disharmony and dysregulation, thereby provoking an unstable perfusion 
pressure, transient ischemia, and reperfusion damage41. These mechanisms, although 
rationale and attractive, need further confirmation.  
Regarding NO-connection with Helicobacter pylori infection (Hp-I), studies in patients 
with Hp-I revealed higher systemic and intraluminal levels of stable NO metabolites.  
This implies that Hp might induce iNOS generation expression42,43. The fundamental 
role of NO in glaucoma or other neurodegenerative disorders and its (over)-generation 
in patients with Hp-I has attracted the interest of recent studies attempting to elucidate 
the pathophysiological link between these conditions.  
The present review aimed to imprint the role of NO in both glaucoma and Hp-I with a 
stimulating approach to motivate future studies attempting to investigate their potential 
relationship and pathophysiology, thereby introducing relative therapeutic strategies. 
 
NO DOUBLE-EDGED SWORD: BENEFICIAL EFFECTS ON OCULAR 
PHYSIOLOGY 
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The range of systematic NO actions in vasodilation and intra- and inter-cellular 
permeability44,45 reflects the mainstay of the beneficial role of NO within the eye, by 
promoting AH outflow. It affects H-TM and SC cell volume and increases AH 
drainage39,40,46. More specifically, H-TM consists of smooth muscle-like cells which 
dilate after NO’s direct signaling39,40 coordinates with the concomitant relaxation of 
smooth muscle cells around the intrascleral vessels. The post-trabecular, distal drainage 
resistance is reduced45.  
In normal conditions, a small quantity (in picomole levels) of NO is generated by 
interactions between L-arginine (as substrate) and nNOS and/or eNOS (as synthetic 
enzymes). NO may activate the mentioned guanyl cyclase to create the c-GMP. 
Consequently, c-GMP induces several biological responses, such as vasodilation, 
increase of ocular blood flow, decrease of IOP, and signal transduction of the nervous 
system47–49. 
Specifically, to chart the ophthalmic distribution of NO and understand its role to IOP 
regulation, NOS subtypes and ocular topography should be defined. eNOS is widely 
expressed in the SC cells, uveal vascular endothelium, H-TM, ciliary body and 
prelaminar region of the optic nerve19,45,50–52. Moreover, nNOS is primarily expressed 
in the inner retina, between the inner nuclear and the ganglion cell layers, with   
predominance in amacrine, bipolar and Müller cells, as well as the limbus, cornea, and 
lens53–55.  On the other hand, iNOS -absent in physiological conditions- is suggested to 
prevail in H-TM, through macrophages after perfusion pressure elevation, and in iris 
via cytokine and endotoxin stimuli. This induces retinal ischemia, inflammation and 
excitotoxicity, in cornea, ciliary body, retinal pigment epithelial cells, and the lamina 
cribrosa astrocytes in established glaucoma45,52,56,57. Figure 1 illustrates the ocular 
locations of NOS subtypes. 
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eNOS is considered as the pivotal component regarding ocular protection against 
glaucoma. Ιt facilitates mechanical decongestion of AH after its generation in H-TM 
by exerting physiological endothelial cell function51,58. The topical improvement of the 
blood flow  (a substantial parameter of glaucoma development) in the optic nerve and 
the ciliary and retinal vessels is succeeded by the autocrine action of eNOS in the 
vascular endothelium, the main source of eNOS51,52,59–63.  
Regarding the protective role of NO in glaucoma, the aspect that the basal endogenous 
expression and release of NO maintain the normal ocular tone and IOP is supported by 
the results of human and animal model studies using NOS inhibitors, such as N-nitro-
L-arginine methylester (L-NAME), N-nitro-L- arginine, and aminoguanidine 64,65. In 
accordance to this, the ophthalmic artery the main ocular irrigation vessel, remains in a 
perpetual dilation as a consequence of a balanced antagonistic action of the mentioned 
vasoactive molecules, NO and ΕΤ36,66. More indirect credentials of the protective role 
of NO in glaucoma emanate from data, underlying the positive effect of NO in patients 
with primary open angle glaucoma (POAG), through relaxation of the H-TM, volume 
regulation, and increase of the permeability of SC. The latter effect is feasible after 
latanoprostene bunod administration, a NO-donating prostaglandin F receptor agonist 
activated in the anterior eye11,59,67–69. Additionally, L-arginine and sepiapterin, through 
their roles as catalytic agents in NO generation, reduce as antioxidants the concentration 
of ROS, such as superoxide or peroxynitrite. This protects H-TM from injury70.  
Evidence from studies on animal models of RGC injury, revealed that Nipradilol offers 
an additional neuroprotection related to the NO by this agent55,71. Specifically, 
Nipradilol [3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3-nitroxy-2H-1-
benzopyran; molecular weight: 326.35], is registered both as a systemic hypotensive 
and an anti-glaucoma agent. It exhibits nonselective b-receptor and selective a-receptor 
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blocking properties with a NO donor action72. The mechanism of its ocular hypotensive 
effects involves inhibition of AH production owing to its b-blocking action and 
increased uveoscleral outflow due to the action of a-blocking agents. Nipradilol has 
vasodilator activity owing to NO release from its nitroxyl moiety. NO liberated from 
the Nipradilol exhibits a nitroglycerine-like vasodilatory action of increased retinal 
blood flow and optic nerve head (ONH) circulation in rabbits72. NO at low 
concentration could mediate the effect of Nipradilol in promoting axonal regeneration 
of RGCs in adult cats72. Specifically, the protective effect of Nipradilol in RGCs 
appears to be mediated by S-nitrosylation of antioxidative-related Keap1 protein due to 
its NO-donating effect. It also has been reported that Nipradilol promoted axon 
outgrowth in cat RGCs. However, whether NO/S-nitrosylation signaling for axonal 
regeneration is unclear72. 
Regarding reduced cornea penetration, short duration of efficacy and limited 
therapeutic index of most NO donors impede their clinical applications in glaucoma 
therapy. Recent studies reported a novel NO-donor delivery system73. This method is 
based on mesoporous silica nanoparticles (MSNs), which may overcome the 
aforementioned problems and deliver the NO-donating drug, sodium nitroprusside 
(SNP) to the target tissues of TM and SC73. In this respect, it has been proposed that 
SNP-MSNs delivery system can induce more exogenous NO and maintain higher NO 
levels in animal eye models. This may lengthen the period of IOP decrease appearing 
to be promising for regulating IOP in patients with POAG and ocular hypertension.  
Likewise, this system may support the development of a new generation of 
nanomedicine for diverse clinic applications including subcutaneous and nasal cavity 
drug delivery73. However, skepticism about possible long-term NO toxic overload 
might limit their therapeutic application and thus further studies are warranted. 
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NO DOUBLE-EDGED SWORD: A CAUSE OF OCULAR 
PATHOLOGY 
In abnormal conditions large amounts of NO (in nanomole levels) are produced by 
iNOS from L-arginine. NO further oxidizes into NO2
-, nitrite, peroxynitrite and free 
radicals to interact with several molecules (i.e. thiols, iron-sulfur centers of several 
enzymes, cytochrome oxidase or glycolytic enzymes). This leads to the modification of 
biological functions of cells, DNA injury, neurotoxicity, optic nerve degeneration, and 
numerous eye diseases, including glaucoma48,49,74. Evidence of abnormal NO 
production in glaucoma is also supported by genetic data indicating consistent 
associations between eNOS-related polymorphisms and POAG75. Increased levels of 
NO to twice normal values were shown in rat retinas with induced glaucoma associated 
with apoptosis and necrosis of RGCs76,77. Additional data support that glaucoma could 
occur due to NO neurotoxic effects at the ONH and retina, leading to a vicious circle 
after ONH degeneration and visual field loss78,79. This appears to be triggered by factors 
like ocular inflammation, LPS, namely a Gram negative endotoxin, or pro-
inflammatory cytokines47–49. 
An attractive approach regarding NO’s harmful role in glaucoma concerns its 
uncontrolled and unstable ocular concentration. Abnormal effects by NO could be 
caused by any quantitative imbalance both increasing and decreasing. Indeed, both 
underproduction and overproduction of NO in eye tissues can occur, leading to ocular 
malfunction and diseases, respectively. Therefore, ocular diseases could be treated by 
making up NO deficiency through NO donors and NO precursors (substrate of NO 
synthases) or reducing overproduction of NO through inhibition of iNOS activity.  
In case of infections, high NO concentration is helpful due to its antimicrobial effect. 
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However, it can trigger, as a proinflammatory signaling molecule, the induction of 
adverse effects14,55. In this regard, studies have demonstrated that exogenous 
administration of direct NO donors or N-methyl-D-aspartate type (NMDA) could be 
responsible for delayed glaucomatous retinal damage, cellular rarefaction in the 
ganglion cell layer, and thinning of the inner plexiform layer80. The mechanism is 
probably mediated via activation of NMDA membrane receptors and indirect 
production of a large amount of NO. It may be inhibited by NO trammeling agents, 
NMDA receptor antagonists or nitro-L- arginine methylester treatment80,81.  
On the other hand, NO absence after endothelial damage, eNOS genetic deficits, or NO 
signaling abnormalities spoils the vasoactive balance with ET, thus increasing 
nonselectively the vascular and tissue resistance and contraction10. In this respect, 
glutamate is a neurotransmitter, the physiologic role of which is to transmit synaptic 
pulses. In pathologic states, it stimulates target cells, causing death (or excitotoxicity)82. 
Excitotoxicity induced by glutamate via NMDA receptors produces large amounts of 
NO. This appears to play an essential role in the neuronal loss in glaucomatous 
neuropathy83. Specifically, glutamate-induced excitotoxicity has been a common 
underlying mechanism in diverse neurological disorders, including glaucoma84. The 
damaging glutamate effect on RGCs has been established by exposing the retina to high 
glutamate concentrations in vitro85 and in vivo86. This effect of glutamate on RGCs 
occurs via interaction with the mentioned glutamate receptors. While excitatory 
receptors are copious in RGCs, under normal circumstances homeostatic mechanisms 
inhibit overexpression of the receptors86,87. Excessive accumulation of glutamate results 
in overstimulation of NMDA receptors. In turn, it induces intracellular calcium influx. 
The resulted complex cascade activation attacks cell components and produces ROS88 
and apoptosis89,90. This is also involved in glaucomatous pathology91. 
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Supporting data from experimental models indicate that there are augmented 
intraocular glutamate levels following acute IOP elevation92. Moreover, evidence from 
some experimental glaucoma models and glaucomatous human eyes indicate high 
glutamate concentrations in the vitreous93. However, other studies show normal levels 
of glutamate in the vitreous of experimental glaucoma94.  
Additional experimental data indicate the presence of ET-1 and high levels of NO in 
AH and vitreous in spontaneous glaucoma whereas the changes in glutamate levels are 
varied95. It is important to note that the peak stimulus for NO release is the activation 
of NMDA receptors by glutamate, whereas glutamate neurotoxicity is mediated, at least 
partly, by NO and mitochondrial damage. This signifies the connection of NO pathways 
with glutamate neurotoxicity96. Based on the evidence, inhibition of glutamate activity 
by modulation of NMDA-type receptors may be an essential strategy for 
neuroprotection97. 
NO excess leads to oxidative reactions with ROS, resulting in the mentioned RNS 
production98–100. This is usually caused by conditions like tissue ischemia-reperfusion 
injury, inflammation and sepsis101. Normal antioxidant clearance mechanisms 
neutralize low concentrations of RNS, such as peroxynitrite, whereas, upon plethoric, 
these radicals use essential cellular molecules as substrate to react (i.e. as proteins, 
cysteine, and glutathione). This provides a stable and extended deposit of NO after S-
nitrosylation and mediating nitrosative stress and biological diversion98.  
In this respect, nitrosative stress, expressed by peroxynitrite activity, has been 
suggested as an important risk factor for glaucoma56. The mainstay of its chemical 
actions, in case of insufficient clearance, is the generation of 3-nitrotyrosine, which is 
additionally used as a diagnostic “footprint” of nitrosative stress detected with 
antinitrotyrosine antibodies77,98,102,103, thus suspecting a long-term exposure to 
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peroxynitrite104. Alternatively, peroxynitrite induces the oxidation of sulfhydryl groups 
and lipids, prevents mitochondrial respiratory circle, and destabilizes cytoskeleton105. 
These chemical pathways have been recognized as pathogenetic to endothelial injury, 
neurotoxicity, and other systemic inflammatory disorders101. Additionally, through 
RNS, NO mediates the pathophysiology and cellular apoptosis in CNS injuries, 
ischemia, infections, and neurodegeneration5,106. Intraocular peroxynitrite anions, in an 
oxidative ocular milieu, disintegrate quickly to toxic hydroxide radicals after reaction 
with oxygen, copper, and iron23. This causes fundamental modifications in H-TM and 
RGC function and architecture, by reacting with cellular molecules98,107. Furthermore, 
except for formatting peroxinitrite, NO can directly induce apoptosis through protein 
and DNA degradation due to its free radical properties58. Regarding the aforementioned 
data, rodent studies revealed a protective role of NOS inhibitors against retinal hypoxia, 
apoptosis and NMDA-induced cell death, thus implying a neurotoxic role of NO79,108. 
Although this effect is more obvious in mice due to their anatomy, NO excess can act 
opposite to its normal decongestive facility on H-TM by relaxing the ciliary 
muscle45,109–111. 
The ocular anterior chamber, as the region of glaucoma development, possesses 
vascular characteristics and expresses the markers of endothelial dysfunction, as in 
other vascular conditions112–114. Endothelial cells’ injury in H-TM consists of the 
vascular component of pathophysiology in glaucoma by provoking further molecular 
cascades and apoptosis of ganglion cells112. 
As stated, the main eNOS action is beneficial by regulating H-TM homeostasis. 
Nevertheless, under exposure to endotoxins, endothelial cells of diminutive vessels 
produce superoxide through eNOS115. eNOS dimers constitute the appropriate form to 
the normal enzymatic function, whereas its monomers – a result of L-arginine or 
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tetrahydrobiopterin penury- affect oxygen by generating hyperoxide116. Additionally, 
studies with glaucoma patients have revealed an impaired nicotin-amide adenine 
dinucleotide phosphate oxidase diaphorase concentration in the conventional outflow 
system and mutations in the eNOS gene, such as eNOS rs2070744 polymorphism 
associated with normal tension glaucoma10,117,118. Likewise, eNOS overproduction in 
iris vessels and decline in H-TM have been revealed in patients with POAG and predicts 
worse outcomes58,62. 
In contrast to the generation and activity of eNOS under physiological conditions, iNOS 
is regulated by cytokines and bacterial signaling molecules in immune reactions against 
infections, inflammation, and tissue hypoxia. It induces an overwhelming and perpetual 
NO formation in macrophages and endothelial cells3,11,20,26. Cellular and extra-cellular 
stress stimulates a plethora of regulative inflammatory molecules, such as the nuclear 
factor kappa-light-chain enhancer of activated B cells (NF-κΒ) and mitogen-activated 
protein kinases respectively, which are both responsible for iNOS triggering17,119.  
• Inflammatory micro-environment, through tumor necrosis factor (TNF)-α and 
other signaling molecules, activates the cytosolic inert NF-κΒ and induces its 
translocation to the nucleus and affixture on iNOS gene promoter, thus resulting 
to its activation and transcription119,120. 
• Activated NF-κB enters the nucleus to provoke transcription of genes that 
mediate varied cellular events, including immunity, inflammatory process, 
proliferation, apoptosis, and cellular senescence31. 
• NF-κB activation is a frequent pathological pathway in several disorders 
characterized by inflammation, including  glaucoma31. 
• NF-κB signaling is activated in response to elevated IOP, vascular disorders, 
and oxidative stress121. 
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• NF-κB activation was detected in human glaucoma ONH astrocytes and 
experimental animal models122,123.  
• Inhibition of NF-κB may decrease inflammatory processes and protect RGCs121. 
Studies in patients with neurodegenerative disorders also suggest a pathogenetic 
contribution of iNOS expression11,124. Likewise, some data indicate that an IOP raise 
induces iNOS generation, thereby strengthening the hypothesis of the vicious circle in 
the relationship between NO and glaucoma. The astrocytes of the ONH express the 
iNOS in vivo among glaucoma patients and glial cells in vitro under mechanical and 
hypoxic stress125. Moreover, studies with rat models of glaucoma support the theory 
that pressure mediated degeneration in glaucoma may be triggered by iNOS 
overexpression by inducing RNS neurotoxicity. The latter is implied by the beneficial 
outcomes of selective inhibitors of iNOS, such as aminoguanidine and the enhanced 
NO level following the elevation of the pressure gradient over the H-TM58,125,126. 
The inadequate perfusion and oxygenation of retina induces iNOS overexpression and 
NO generation. This results in cytotoxicity, apoptosis, axonal damage and visual field 
changes56. Patients with POAG exhibit an elevated concentration of nitrotyrosine and 
an analogous deficit of visual fields to the iNOS expression and activity in the H-TM60. 
Furthermore, multifocal ocular location of iNOS has been disclosed in glaucoma 
patients astrocytes of the ONH, microglia, endothelial cells of iris capillaries, AH, and 
H-TM60,61. Once iNOS production is induced in astrocytes and microglia, as a result of 
inflammation and stress related signaling molecules, a large amount of NO is generated. 
It demolishes neural cells through apoptosis and parthanatos11. As S-nitrosylation of 
cellular functional proteins occurs, a cascade triggers tumor suppressor p53 production 
and results in p53-dependent apoptotic cell death. Moreover, the NO-excess dependent 
 18 
peroxynitrite acts directly and destructively on DNA, thus promoting parthanatos 
induction11. 
Important to note, the crucial role of NO toxicity as the initiator of ONOO
−
 mediated 
parthanatos in a variety of neurologic conditions14. Parthanatos (derived from thanatos 
[Greek θάνατος] the personification of death in Greek mythology) is characterized by 
poly (ADP-ribose) polymerase-1 (PARP-1), a DNA damage-sensing enzyme, 
activation, PAR translocation from the nucleus to the mitochondria that ultimately 
results in mitochondrial depolarization, and large-scale DNA fragmentation, the final 
step in the execution of parthanatos. NO kills neurons via parhanatos127, playing an 
important role in several neurodegenerative disorders128. 
 Beyond parthanatos and mitochondrial permeability transition, other mechanisms 
involved in neuronal death include intrinsic and extrinsic pathways of apoptotic 
process, autophagy, phagoptosis (phagocytosis), oncosis, necroptosis, ferroptosis, 
sarmoptosis, autosis, autolysis, paraptosis, and pyroptosis129. NO has been implicated 
in the aforementioned mechanisms14,130–135. Figure 2 charts the pathways related to NO 
concentration fluctuations. 
Hp IN NO-RELATED GLAUCOME PATHOPHYSIOLOGY 
Hp selectively infects and colonizes mostly the gastric epithelium, oral cavity, and 
intestinal epithelium. It is strongly involved in the development of pathologies, 
particularly upper or lower gastrointestinal tracts and a variety of systemic disorders 
and  neurodegenerative diseases like Alzheimer’s disease (AD) or glaucoma136–138. 
Behaving as microbiota, Hp and its virulent products induce lasting chronic 
gastrointestinal inflammatory processes and systemic inflammatory reactions by 
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orchestrating and modifying the character of immune system responses. Therefore, it 
contributes to the pathophysiology of gastrointestinal and systemic disorders136,138–140.  
In this respect, beyond gastrointestinal pathologies, active Hp-I induces humoral and 
cellular immune responses. Owing to the sharing of homologous epitopes to the host 
antigens (molecular mimicry), it cross-reacts with components of peripheral and brain 
nerves contributing and potentially perpetuating neural tissue damage observed in 
diseases like Guillain-Barré syndrome (GBS) and AD141–143. Molecular mimicry may 
also play a role in glaucoma pathophysiology144. 
Regarding Hp-related iNOS, several studies have reported iNOS increased production 
following Hp-I in both humans and animals. The up-regulated iNOS production results 
in an increase of NO production. This may lead to the increase of DNA damage and 
apoptosis. In this respect, classification of iNOS expression in the gastric mucosa could 
be used clinically to identify patients with a high risk for gastric malignancy. The host 
will attempt to terminate the infection by activating the mucosal generation of the 
cytotoxic RNS. In the extracellular space, NO released from macrophages can eliminate 
Hp145. An effective increased production of NO and oxy-radicals results in bacterium 
eradication. Nevertheless, Hp persists in the host, inducing a lasting chronic 
inflammatory reaction that could be deleterious to the host.  
The point that Hp survives in this hostile environment (despite upregulation of iNOS) 
indicates that this pathogen has developed strategies to avoid NO-dependent 
eradication. Several studies have reported on the complexity of the Hp response to 
oxidative and nitrosative stress. Specific proteins transcripted by Hp enable the 
pathogen to cope with the damaging effects of NO. These systems are part of the 
pathogen protection against nitrosative stress146. Likewise, Hp may exhibit a direct 
effect on reduction in gastric mucosal blood flow by inhibiting NO production by iNOS, 
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thereby decreasing the vasodilatory and mast cell stabilizing action of NO147. Moreover, 
several Hp virulence agents contribute to its ability to evade the immune system and 
disrupt the host’s cells.  
One of the most known and well-studied Hp virulence agents, urease, modulates iNOS 
expression and NO release by inflammatory cells, hampering phagocytosis by gastric 
macrophages148,149. Hp urease induces NO and ROS production by endothelial cells150. 
Hp is highly adapted to surviving in the gastric environment; a key adaptation is its 
virulence agent urease151. Urease is  a crucial index in the capacity of Hp to avoid 
bactericidal activity of gastric acid acidity152. Moreover, glutamate appears to be an 
essential immunomodulator during Hp-I and Hp-related γ-glutamyltranspeptidase (an 
important enzyme for its colonization). It induces a tolegenic effect via activation of 
glutamate receptors153. Justino et al.146 were the first to describe HP0013, an enzyme 
that catalyzes and degenerates NO, which reduces iNOS-dependent immunity against 
Hp. The degradation of NO in the gastric environment could function as a feedback 
signal to iNOS. This occurs during a plethora of (patho-) physiological processes, 
leading to an increased and unlimited production of NO systematically and 
intraocularly. It requires targeted evaluation to confirm.  
Another studied virulence agent is cytotoxin-associated gene A (CagA). This 
manipulates a subset of fundamental cell processes including adhesion, polarity, 
proliferation and motility, receptor mediated endocytosis, cytoskeletal rearrangements, 
inflammation, apoptosis, and cell cycle progression154. The presence of CagA leads to 
an increased risk of gastric carcinogenesis155. Increased hydrogen peroxide levels and 
oxidative DNA damage have been described in CagA-positive strains156,157.   
Vacuolating cytotoxin A (VacA) is a third well-studied virulence agent. It is capable of 
inducing an influx of Ca2+ and generation of ROS that leads to NF-κB activation, 
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thereby increasing proinflammatory immune response158. Likewise, VacA with 
additional Hp factors, acts as immune modulators that impair the activation and 
proliferation of a diversity of immune cells, including T lymphocytes. This suggests 
essential roles in immune suppression and evasion. Such diverse immune functions of 
VacA accentuate its significant role in the tempering of an immune response, thereby 
facilitating Hp colonization to the gastric epithelium, as well as its potential 
immunomodulatory role on extragastric disorders159. In particular, the ability of VacA-
proficient Hp to skew T-cell responses toward regulatory T-cells (Tregs) indicates that 
Hp-I may contribute to pathogen immune escape by increasing gastric Treg 
response159,160.  
The inability of the host to eradicate the infection leads to a chronic inflammatory state 
with sustained oxidative stress within the tissue. ROS and RNS, induced by the immune 
and epithelial cells, damage the host cells and lead to DNA damage. Hp has evolved to 
evoke this damaging process while reducing the mentioned host’s efforts to kill the 
pathogen. This long-lasting process with inflammation and oxidative stress can lead to 
gastric oncogenesis161.  
Beyond the topical level, studies have reported positive antibodies against Hp related 
VacA both in serum and CSF of patients with the mentioned GBS syndrome and 
delayed F-wave latencies142. The target molecules of the specific antibody against VacA 
in the CSF of GBS patients are probably associated with components of the peripheral 
nerve myelin, indicating a role in the immune responses of patients with the 
demyelinating form of GBS. Hp could induce the mentioned humoral and cellular 
immune responses that, due to molecular mimicry, cross-react with ganglioside surface 
components of peripheral nerves. Immune reactions against target epitopes in the 
surface membranes of Schwann cells or myelin lead to GBS162. Importantly, molecular 
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mimicry of host structures by the LPS’s saccharide part of the gastrointestinal 
pathogens Hp and Cambylobacer jejuni are connected with the development of 
autoimmune sequelae observed in GBS163. Cambylobacer jejuni may also be involved 
in glaucoma pathophysiology164. 
Apart from NO, molecular mimicry, and cross-reactivity, Hp-I could influence the 
pathophysiology of GBS, brain neurodegenerative disorders and glaucoma via 
numerous other mechanisms, including the release of proinflammatory and vasoactive 
substances acting at a distance136,142,165.  
The authors reported a strong correlation between AH and serum specific anti-Hp IgG 
levels in patients with glaucoma. Therefore, the authors hypothesize that Hp antibodies 
may circulate in the bloodstream and enter the aqueous circulation via blood AH 
barrier. In AH, they could reach a substantial level sufficient to impact the development 
or progression of glaucoma166. Other studies also reported that autoimmune injury to 
the optic nerve could occur directly by autoantibodies or indirectly by system of a 
mimicked autoimmune response to a sensitizing antigen, damaging RGCs167,168. 
Hp-I and glaucoma share common pathophysiological events. Therefore, it is enough 
to consider the hypothesis of causal dependence between these conditions. As a relative 
example, cellular death in both gastric and ocular epithelium, namely in Hp-I and 
glaucoma pathologies , follows a pathway of mitochondrial oxidative stress169. 
Oxidative stress affects mitochondrial and endosomal membranes due to their 
interaction. However, the direct apoptotic pathway remains unclear170.  
Relative studies indicate that, beyond Hp-related RNS action that induces gradual local 
tissue damage and gastric carcinogenesis171, chronic Hp-I, characterized by fluctuated 
severity over time, induces alterations in NO concentration. A perpetual generation and 
action of RNS also contributes to an unstable perfusion pressure in ocular arteries, 
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transient ischemia and reperfusion damage41. Moreover, several strains of Hp stimulate 
vascular endothelial growth factor (VEGF) expression. This is related to worse gastric 
outcomes and may contribute to the ocular upregulation of NO by VEGF172,173.  
Once triggered174, VEGF activates its endothelial receptors; and a downstream 
sequence increases the concentration of NO10. VEGF appears to be involved in 
glaucoma pathophysiology175.  In this regard, the known vascular burden of Hp-I could 
affect the H-TM endothelium by the induction of the synthesis of tissue factors, cell-
surface thrombin, platelet adherence, adhesion molecules, cytokines, and growth 
factors like VEGF, as well as inhibition of prostacyclin176,177.  Proinflammatory 
cytokines involved during Hp-I enhance the possibility of vascular diseases. 
Eradication treatment could ameliorate endothelial injury 176,178. 
The Hp-I induced iNOS up-regulation considered with the aforementioned role of 
iNOS in glaucoma could propose inductively iNOS as the “common denominator” of 
these conditions, though necessitating experimental evaluation. 
Viewing the aforementioned data, the following Hp-related NO cascade, summarized 
in Figure 3, seems to take place in glaucoma pathophysiology: 
Upon Hp gastric mucosa colonization, immune response is induced. Mucosal 
immigration of macrophages and lymphocytes producing iNOS also takes place179.  
Once lymphocytes, plasma cells and macrophages are chemotactically triggered, iNOS 
generation is performed, as deduced by elevated concentrations of NO metabolites in 
Hp infected patients42,43,179,180. Chronic antigenic stimuli, such as superficial bacterial 
LPS upon exposure to inflammatory cells regulates iNOS expression in order to 
generate NO and RNS. This is especially true with peroxynitrite, which attempts to 
eliminate the pathogen149,179,180, although Hp could escape such attacks.  
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Persistent Hp-I could promote the expression of iNOS, producing large amounts of NO, 
inducing DNA damage and gastric pathologies181–185. Hp-I induces damage in the 
stomach and duodenum by releasing soluble factors. This activates inflammatory cells, 
including neutrophils, to produce cytotoxic mediators like NO and superoxide186.  
NO, a rapidly diffusing gas, appears to be a potent neurotoxin that may contribute to 
demyelination and neurodegeneration187. Specifically, NO is diffused effortlessly in the 
systematic circulation- as implied, for instance, by studies in animal models of cirrhosis 
and patients with advanced cirrhosis188,189. Therefore, is also diffused in the retina as a 
potential agent of RGC apoptosis in the glaucomatous eye190.  
Additionally, chronic inflammation by Hp-I releases inflammatory mediators being 
incriminated to disrupt the blood–retinal barrier (BRB)191. More specifically, Hp-
induced cytotoxin VacA displays chemotactic activities to the bone marrow-derived 
mast cells (BMDMCs) and induces the BMDMCs to produce proinflammatory 
cytokines like TNF-α, interleukin-6 and other mediators like  VEGF which disrupt the 
blood-brain barrier leading to the development of degenerative diseases, including AD 
and glaucoma165.  
 Proinflammatory cytokines like TNF-α released in Hp-I to increase particularly the 
permeability of BRB, rendering the retina vulnerable to other harmful agents and 
contributing to the pathogenesis of glaucoma192–194.  
After BRB damage, vasoactive substances, such as ET and NO, are released and 
aggregated intraocularly, thereby causing vasoconstriction induced ischemia of the 
optic nerve and dysregulation of ophthalmic artery tone. This promotes increment of 
IOP74,190,191.   
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Furthermore, the nasal and oral cavity are known reservoirs of Hp by which the 
bacterium translocates in the anterior surface of the eye, inducing eye pathologies195–
198. Likewise, Hp may access the brain via the oral-nasal-olfactory pathway leading to 
neurodegeneration192. An original study199 revealed Hp contamination and neutrophilic 
and lymphocytic infiltration in the H-TM and iris tissue of glaucomatous patients after 
surgical intervention. This suggests an Hp-I induced chronic inflammatory process 
leading to glaucomatous damage. The direct ocular colonization by Hp could induce 
local inflammation, iNOS generation and nitrosative stress. In this respect, some studies 
reported that augmented levels of toxic autoantibodies recognize glycosaminoglycans 
of the ONH in glaucoma patients could increase the susceptibility of the ONH to 
damage by altering the functional properties of the lamina cribrosa, its vasculature, or 
both 168. Likewise, high title of the mentioned specific anti-Hp IgG potentially toxic 
antibodies in AH might also contribute to glaucoma severity166. These data, however, 
are warranted further research in depth. 
Finally, regarding the mentioned parthanatos-related PAR (PAR-1/PAR-2), it also 
appears to play an essential role in Hp gastric mucosa adhesion and Hp-associated 
pathologies200; Hp may activate PARs, which contributes to the Hp-related pathological 
responses201. Specifically, PAR-2 is involved in neuroinflammation202. Moreover, 
PAR-1 is located in specific neuronal populations and glial cells and its activation could 
induce neurite retraction in olfactory neurons203. The latter might promote Hp access 
brain via nasal-olfactory pathway. This induces brain pathologies192. It is further 
supported by experimental studies that indicate that PAR-1 deficient mice are resistant 
to neuronal damage and neurologic deficits in a cerebral hypoxia/ischemia model204,205.  
CONCLUSION 
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NO acts bidirectionally in ocular milieu, thus provoking or protecting from glaucoma. 
The dominant NOS subtype and environmental conditions are the main regulators of 
its function. Additionally, chronic Hp-I irrigates a perpetual and fluctuating NO 
production, contributing to nitrosative stress. The epidemiological connection between 
Hp-I and glaucoma166,206–209, combined with the indications of both remote and local 
regulation of ocular NO by Hp, encourage the elaboration of further studies to 
substantiate and elucidate the suggested relationship. However, the pathogenesis of 
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